Understanding the lineage of the CD45+ EpCAM+ BM population as well as the mechanisms responsible for the migration of this population to the thymus and how they contribute to the maintenance of TEC number and organization will be critical in counteracting age-associated involution, particularly in cancer patients, due to enhanced degeneration in response to therapy. This evidence concerns the gene EPCAM and cancer.